Q1: 2026-04-30 Earnings Summary
EPS of $8.55 beats by $1.76
|
Revenue of
$19.80B
(55.55% Y/Y)
beats by $1.99B
Eli Lilly and Company (LLY) Q1 2026 Earnings Call April 30, 2026 10:00 AM EDT
Company Participants
Mike Czapar - Director of Investor Relations
David Ricks - Chairman & CEO
Lucas Montarce - Executive VP & CFO
Daniel Skovronsky - Chief Scientific & Product Officer and President of Lilly Research Laboratories
Patrik Jonsson - Executive VP & President of Lilly International
Kenneth Custer - Executive VP & President of Lilly Cardiometabolic Health
Ilya Yuffa - Executive VP and President of Lilly USA & Global Customer Capabilities
Conference Call Participants
Geoffrey Meacham - Citigroup Inc., Research Division
Christopher Schott - JPMorgan Chase & Co, Research Division
Seamus Fernandez - Guggenheim Securities, LLC, Research Division
Alexandria Hammond - Wolfe Research, LLC
Evan Seigerman - BMO Capital Markets Equity Research
Asad Haider - Goldman Sachs Group, Inc., Research Division
James Shin - Deutsche Bank AG, Research Division
Mohit Bansal - Wells Fargo Securities, LLC, Research Division
Terence Flynn - Morgan Stanley, Research Division
Umer Raffat - Evercore ISI Institutional Equities, Research Division
Courtney Breen - Bernstein Institutional Services LLC, Research Division
David Risinger - Leerink Partners LLC, Research Division
Presentation
Operator
Ladies and gentlemen, thank you for standing by, and welcome to the Lilly Q1 2026 Earnings Conference Call. [Operator Instructions] I would now like to turn the conference over to your host, Mike Czapar, Senior Vice President of Investor Relations. Please go ahead.
Mike Czapar
Director of Investor Relations
Good morning. Thank you for joining us for Eli Lilly and Company's Q1 2026 Earnings Call. I'm Mike Czapar, Senior Vice President of Investor Relations. Joining me on today's call are Dave Ricks, Lilly's Chair and CEO; Lucas Montarce, Chief Financial Officer; Dr. Dan Skovronsky, Chief Scientific and Product Officer; Adrienne Brown, President of Lilly Immunology, Dr. Carole Ho, President of Lilly Neuroscience; Ilya Yuffa, President of Lilly U.S.A. and Global Customer capabilities; Jake Van Naarden, President of Lilly Oncology and Head of Business Development; Patrik Jonsson, President of Lilly International; and Ken Custer, President of Lilly Cardiometabolic Health.
此内容由惯性聚合(RSS阅读器)自动聚合整理，仅供阅读参考。 原文来自 — 版权归原作者所有。